Clinical data | |
---|---|
Trade names | Tonocard |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a601248 |
ATC code | |
Pharmacokinetic data | |
Bioavailability | 0.9-1 (oral) |
Protein binding | 10-20% |
Metabolism | glucuronidation (primary) |
Elimination half-life | 9-14 R, 13-20 S |
Excretion | 30-50% urine (unchanged) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.050.441 |
Chemical and physical data | |
Formula | C11H16N2O |
Molar mass | 192.262 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Tocainide (Tonocard) is a class Ib antiarrhythmic agent. It is no longer sold in the United States.
Tocainide is a lidocaine derivative, that undergoes very less first pass metabolism. It occurs as two enantiomers. The R isomer is three times more potent than the S isomer. [5] Tocainide's oral bioavailability is almost 100%. [6] Plasma half-life generally lasts for 11.5-15.5 hours (13.5 ± 2 hours [7]). In the blood, tocainide is 10-20% protein bound. [8] [6] The volume of distribution is 2.8-3.2 L/kg. [8] 31-45% is excreted unchanged in the urine. [8] The more active R-isomer is cleared faster in anephric patients (without kidneys) or those with severe kidney dysfunction. The main metabolite is tocainide carbamoyl ester glucuronlde. [9]
Rifampicin increases conversion of tocainide into its main metabolite, tocainide carbamoyl ester glucuronlde, [9] by inducing the glucuronosyl transferase enzyme that catalyzes glucuronidation of tocainide to produce that metabolite. Rifampicin also increases elimination rate and decreases oral clearance of tocainide. [10] Tocainide decreases plasma clearance of theophylline. [11]
Clinical data | |
---|---|
Trade names | Tonocard |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a601248 |
ATC code | |
Pharmacokinetic data | |
Bioavailability | 0.9-1 (oral) |
Protein binding | 10-20% |
Metabolism | glucuronidation (primary) |
Elimination half-life | 9-14 R, 13-20 S |
Excretion | 30-50% urine (unchanged) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.050.441 |
Chemical and physical data | |
Formula | C11H16N2O |
Molar mass | 192.262 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Tocainide (Tonocard) is a class Ib antiarrhythmic agent. It is no longer sold in the United States.
Tocainide is a lidocaine derivative, that undergoes very less first pass metabolism. It occurs as two enantiomers. The R isomer is three times more potent than the S isomer. [5] Tocainide's oral bioavailability is almost 100%. [6] Plasma half-life generally lasts for 11.5-15.5 hours (13.5 ± 2 hours [7]). In the blood, tocainide is 10-20% protein bound. [8] [6] The volume of distribution is 2.8-3.2 L/kg. [8] 31-45% is excreted unchanged in the urine. [8] The more active R-isomer is cleared faster in anephric patients (without kidneys) or those with severe kidney dysfunction. The main metabolite is tocainide carbamoyl ester glucuronlde. [9]
Rifampicin increases conversion of tocainide into its main metabolite, tocainide carbamoyl ester glucuronlde, [9] by inducing the glucuronosyl transferase enzyme that catalyzes glucuronidation of tocainide to produce that metabolite. Rifampicin also increases elimination rate and decreases oral clearance of tocainide. [10] Tocainide decreases plasma clearance of theophylline. [11]